LB Pharmaceuticals Inc SEC filings LBRX
LB Pharmaceuticals Inc has 143 filings in SEC EDGAR's recent list, going back to Dec 15, 2016. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Oct 13, 2026 | Oct 9, 2026 |
| 4 | Insider transaction | Oct 13, 2026 | Oct 9, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 13, 2026 | — |
| 3 | Initial insider ownership | Sep 24, 2026 | Sep 14, 2026 |
| 3 | Initial insider ownership | Sep 14, 2026 | Sep 2, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| 4 | Insider transaction | Aug 3, 2026 | Jul 30, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 29, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 16, 2026 | — |
| 144 | Notice of proposed sale | Jun 9, 2026 | — |
| 4 | Insider transaction | Jun 5, 2026 | Jun 3, 2026 |
| 4 | Insider transaction | Jun 5, 2026 | Jun 3, 2026 |
| 4 | Insider transaction | Jun 5, 2026 | Jun 3, 2026 |
| 4 | Insider transaction | Jun 5, 2026 | Jun 3, 2026 |
| 4 | Insider transaction | Jun 5, 2026 | Jun 3, 2026 |
| 4 | Insider transaction | Jun 5, 2026 | Jun 3, 2026 |
| 4 | Insider transaction | Jun 5, 2026 | Jun 3, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 13, 2026 | — |
| 4 | Insider transaction | Mar 10, 2026 | Mar 6, 2026 |
| 3 | Initial insider ownership | Mar 10, 2026 | Mar 6, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 10, 2026 | — |
| 4 | Insider transaction | Feb 10, 2026 | Feb 6, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 21, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 21, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 21, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Dec 31, 2025 | — |
| 4 | Insider transaction | Dec 11, 2025 | Dec 10, 2025 |
| 3 | Initial insider ownership | Nov 18, 2025 | Nov 10, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 17, 2025 | — |
| 4 | Insider transaction | Sep 29, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 29, 2025 | Sep 10, 2025 |
| SCHEDULE 13D | Ownership over 5% (active) | Sep 25, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 19, 2025 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Sep 19, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 18, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 18, 2025 | — |
| 4 | Insider transaction | Sep 16, 2025 | Sep 12, 2025 |
| 3 | Initial insider ownership | Sep 16, 2025 | Sep 12, 2025 |
| 4 | Insider transaction | Sep 16, 2025 | Sep 12, 2025 |
| 4 | Insider transaction | Sep 16, 2025 | Sep 12, 2025 |
| 4 | Insider transaction | Sep 16, 2025 | Sep 12, 2025 |
| 4 | Insider transaction | Sep 12, 2025 | Sep 10, 2025 |
| 4 | Insider transaction | Sep 12, 2025 | Sep 10, 2025 |
| 4 | Insider transaction | Sep 12, 2025 | Sep 10, 2025 |
| 4 | Insider transaction | Sep 12, 2025 | Sep 10, 2025 |
| 4 | Insider transaction | Sep 12, 2025 | Sep 10, 2025 |
| 4 | Insider transaction | Sep 12, 2025 | Sep 10, 2025 |
| 4 | Insider transaction | Sep 12, 2025 | Sep 10, 2025 |
| 4 | Insider transaction | Sep 12, 2025 | Sep 10, 2025 |
| 4 | Insider transaction | Sep 12, 2025 | Sep 10, 2025 |
| 4 | Insider transaction | Sep 12, 2025 | Sep 10, 2025 |
| 4 | Insider transaction | Sep 12, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 11, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 11, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 11, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 10, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 10, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 10, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 10, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 10, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 10, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 10, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 10, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 10, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 10, 2025 | Sep 10, 2025 |
| 3 | Initial insider ownership | Sep 10, 2025 | Sep 10, 2025 |
Showing 70 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LBRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1691082
- Former names
- LB PHARMACEUTICALS INC. (until Dec 12, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.